ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BPTH Bio Path Holdings Inc

2.69
-0.23 (-7.88%)
Last Updated: 15:50:09
Delayed by 15 minutes

Period:

Draw Mode:

Volume 301,805
Bid Price 2.64
Ask Price 2.69
News -
Day High 2.85

Low
2.60

52 Week Range

High
44.80

Day Low 2.60
Company Name Stock Ticker Symbol Market Type
Bio Path Holdings Inc BPTH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.23 -7.88% 2.69 15:50:09
Open Price Low Price High Price Close Price Prev Close
2.81 2.60 2.85 2.92
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,586 301,805 $ 2.72 $ 820,033 - 2.60 - 44.80
Last Trade Time Type Quantity Stock Price Currency
15:50:46 1 $ 2.6899 USD

Bio Path Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.85M 678.80k - 0 -16.08M -23.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Bio Path News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BPTH Message Board. Create One! See More Posts on BPTH Message Board See More Message Board Posts

Historical BPTH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.887.66992.604.1817,344,043-0.19-6.60%
1 Month3.737.66992.604.184,588,923-1.04-27.88%
3 Months8.609.98752.604.321,568,196-5.91-68.72%
6 Months13.02614.7982.605.14820,682-10.34-79.35%
1 Year28.0044.802.6010.671,146,517-25.31-90.39%
3 Years123.80172.3982.6040.24527,073-121.11-97.83%
5 Years360.00486.802.6093.48527,841-357.31-99.25%

Bio Path Description

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

Your Recent History

Delayed Upgrade Clock